A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: Preliminary results of RTOG P-0019

Journal Article · Wed Mar 01 04:00:00 EST 2006 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/J.IJROBP.2005.0· OSTI ID:20793349

Lee, W Robert ^[1]; De Silvio, Michelle ^[2]; Lawton, Colleen ^[3]; Gillin, Michael ^[4]; Morton, Gerard ^[5]; Firat, Selim ^[6]; Baikadi, Madhava ^[6]; Kuettel, Michael ^[7]; Greven, Kathryn ^[1]; Sandler, Howard ^[8]

---

1. Wake Forest University School of Medicine, Winston-Salem, NC (United States)
2. Radiation Therapy Oncology Group, Philadelphia, PA (United States)
3. Medical College of Wisconsin, Milwaukee, WI (United States)
4. M.D. Anderson Hospital, Houston, TX (United States)
5. Toronto-Sunnybrook Regional Cancer Center, Toronto, ON (Canada)
6. Albert Einstein School of Medicine, Philadelphia, PA (United States)
7. Roswell Park Cancer Center, Buffalo, NY (United States)
8. University of Michigan, Ann Arbor, MI (United States)

Purpose: To estimate the rate of acute and late Grade 3-5 genitourinary and gastrointestinal toxicity after treatment with external beam radiotherapy and permanent source brachytherapy in a multi-institutional, cooperative group setting. Methods and Materials: All patients were treated with external beam radiotherapy (45 Gy in 25 fractions), followed 2-6 weeks later by an interstitial implant using {sup 125}I to deliver an additional 108 Gy. Late genitourinary toxicity was graded according to the Common Toxicity Criteria Version 2.0, and the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation morbidity scoring system was used for all other toxicity. Results: A total of 138 patients from 28 institutions were entered on this study. Acute toxicity information was available in 131 patients, and 127 patients were analyzable for late toxicity. Acute Grade 3 toxicity was documented in 10 of 131 patients (7.6%). No Grade 4 or 5 acute toxicity has been observed. The 18-month month estimate of late Grade 3 genitourinary and gastrointestinal toxicity was 3.3% (95% confidence interval, 0.1-6.5). No late Grade 4 or 5 toxicity has been observed. Conclusions: The acute and late morbidity observed in this multi-institutional, cooperative group study is consistent with previous reports from single institutions with significant prostate brachytherapy experience.

• OSTI ID: 20793349
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 3 Vol. 64; ISSN IOBPD3; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
BRACHYTHERAPY
CARCINOMAS
DISEASE INCIDENCE
HAZARDS
IODINE 125
PATIENTS
PROSTATE
RADIATION SOURCE IMPLANTS
TOXICITY